drugset / Trial / NCT00269841
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of anti-TNF chimeric monoclonal antibody (cA2) compared to placebo in the treatment of patients with fistulizing Crohn's disease.
Timeline
- Start
- 1996-05
- Primary completion
- 1998-02
- Completion
- 1998-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Infliximab | Monoclonal antibody | 10 mg/kg | Intravenous |